Sun keeps tabs on Taro facility sale

Sun Pharmaceuticals wrote a second letter to Taro, citing major concerns about the sale of Taro's Irish facility. The letter specifically requests full disclosure of all facts related to the sale. 

In the letter, written to Dr. Barrie Levitt, Chairman of the Board of Directors of Taro, Dilip Shanghvi, Chairman and Managing Director said, "Taro has been unable to address our substantive objections to the proposed sale of Taro's Irish subsidiary ("Taro Ireland"). Instead, you have tried to deflect attention from the logic of our reasoning by accusing us of breaching our duty of good faith to Taro and its other shareholders," adding, "We find this laughable."

The letter follows termination of a merger agreement between the two companies.

- read the letter at the Sun Herald
- get more from Trading Markets

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.